Skye Other Current Assets vs Other Current Liab Analysis

SKYE Stock

USD 4.41 0.13 3.04%

Skye Bioscience, financial indicator trend analysis is much more than just breaking down Skye Bioscience, Common prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Skye Bioscience, Common is a good investment. Please check the relationship between Skye Bioscience, Other Current Assets and its Other Current Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Other Current Assets vs Other Current Liab

Other Current Assets vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Skye Bioscience, Common Other Current Assets account and Other Current Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Skye Bioscience,'s Other Current Assets and Other Current Liab is 0.34. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Skye Bioscience, Common, assuming nothing else is changed. The correlation between historical values of Skye Bioscience,'s Other Current Assets and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Skye Bioscience, Common are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Other Current Assets i.e., Skye Bioscience,'s Other Current Assets and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.34

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Other Current Liab

Most indicators from Skye Bioscience,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Skye Bioscience, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

At present, Skye Bioscience,'s Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Tax Provision	2.1K	6.7K	3.6K	3.0K
Income Tax Expense	2.1K	6.7K	3.6K	2.8K

Tax Provision Income Tax Expense

Skye Bioscience, fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Other Liab	Cash	Non Current Assets Total	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Long Term Debt	Capital Stock	Property Plant And Equipment Net	Short Long Term Debt Total
Other Current Liab		0.9	-0.21	-0.53	0.3	-0.56	0.34	0.55	0.43	0.25	0.37	0.44	-0.83	-0.5	0.07	0.35	0.39	0.48	0.97	-0.42	0.36	-0.86	0.19	0.13	0.36	0.39
Total Current Liabilities	0.9		0.17	-0.81	0.52	-0.71	0.66	0.82	0.74	0.28	0.69	0.66	-0.6	-0.65	0.13	0.68	0.35	0.25	0.95	-0.1	0.71	-0.67	0.19	0.14	0.62	0.63
Net Tangible Assets	-0.21	0.17		-0.67	0.74	-0.45	0.57	0.63	0.76	0.39	0.79	0.73	0.65	-0.53	0.34	0.77	0.11	-0.37	0.01	0.9	0.73	0.58	0.02	0.33	0.75	0.6
Retained Earnings	-0.53	-0.81	-0.67		-0.69	0.81	-0.87	-0.99	-0.95	-0.3	-0.9	-0.86	0.08	0.82	-0.28	-0.91	-0.18	0.07	-0.69	-0.46	-0.93	0.15	-0.11	-0.14	-0.85	-0.85
Accounts Payable	0.3	0.52	0.74	-0.69		-0.53	0.4	0.64	0.78	0.74	0.83	0.86	0.17	-0.56	0.3	0.73	0.57	0.16	0.49	0.49	0.65	0.09	0.34	0.7	0.81	0.57
Other Assets	-0.56	-0.71	-0.45	0.81	-0.53		-0.52	-0.84	-0.77	-0.5	-0.67	-0.73	0.16	0.89	-0.42	-0.67	-0.35	-0.21	-0.66	-0.35	-0.61	0.2	0.09	-0.33	-0.64	-0.54
Other Current Assets	0.34	0.66	0.57	-0.87	0.4	-0.52		0.83	0.78	-0.18	0.75	0.61	-0.05	-0.49	0.01	0.82	-0.2	-0.4	0.48	0.37	0.94	-0.11	0.14	-0.32	0.68	0.88
Other Stockholder Equity	0.55	0.82	0.63	-0.99	0.64	-0.84	0.83		0.94	0.32	0.87	0.85	-0.1	-0.88	0.36	0.89	0.19	-0.05	0.7	0.46	0.89	-0.17	0.01	0.14	0.82	0.8
Total Current Assets	0.43	0.74	0.76	-0.95	0.78	-0.77	0.78	0.94		0.43	0.98	0.93	0.09	-0.79	0.48	0.98	0.19	-0.15	0.61	0.59	0.93	0.01	0.16	0.29	0.94	0.8
Common Stock	0.25	0.28	0.39	-0.3	0.74	-0.5	-0.18	0.32	0.43		0.44	0.55	0.08	-0.56	0.48	0.31	0.79	0.55	0.33	0.29	0.12	0.05	0.04	0.98	0.41	-0.02
Property Plant Equipment	0.37	0.69	0.79	-0.9	0.83	-0.67	0.75	0.87	0.98	0.44		0.93	0.14	-0.68	0.44	0.99	0.21	-0.2	0.56	0.59	0.93	0.06	0.24	0.33	0.95	0.78
Total Assets	0.44	0.66	0.73	-0.86	0.86	-0.73	0.61	0.85	0.93	0.55	0.93		0.13	-0.77	0.56	0.91	0.27	-0.08	0.62	0.59	0.81	0.06	0.26	0.43	0.98	0.8
Total Stockholder Equity	-0.83	-0.6	0.65	0.08	0.17	0.16	-0.05	-0.1	0.09	0.08	0.14	0.13		0.05	0.34	0.15	-0.27	-0.57	-0.7	0.83	0.07	0.99	-0.09	0.14	0.2	0.02
Other Liab	-0.5	-0.65	-0.53	0.82	-0.56	0.89	-0.49	-0.88	-0.79	-0.56	-0.68	-0.77	0.05		-0.57	-0.68	-0.33	-0.19	-0.6	-0.48	-0.59	0.09	0.19	-0.37	-0.67	-0.52
Cash	0.07	0.13	0.34	-0.28	0.3	-0.42	0.01	0.36	0.48	0.48	0.44	0.56	0.34	-0.57		0.47	-0.06	-0.14	0.14	0.57	0.23	0.33	0.02	0.39	0.55	0.16
Non Current Assets Total	0.35	0.68	0.77	-0.91	0.73	-0.67	0.82	0.89	0.98	0.31	0.99	0.91	0.15	-0.68	0.47		0.06	-0.31	0.53	0.61	0.96	0.07	0.22	0.19	0.95	0.83
Common Stock Shares Outstanding	0.39	0.35	0.11	-0.18	0.57	-0.35	-0.2	0.19	0.19	0.79	0.21	0.27	-0.27	-0.33	-0.06	0.06		0.65	0.41	-0.14	-0.01	-0.31	-0.19	0.79	0.12	-0.11
Non Current Liabilities Total	0.48	0.25	-0.37	0.07	0.16	-0.21	-0.4	-0.05	-0.15	0.55	-0.2	-0.08	-0.57	-0.19	-0.14	-0.31	0.65		0.4	-0.49	-0.35	-0.54	0.12	0.55	-0.26	-0.36
Total Liab	0.97	0.95	0.01	-0.69	0.49	-0.66	0.48	0.7	0.61	0.33	0.56	0.62	-0.7	-0.6	0.14	0.53	0.41	0.4		-0.23	0.54	-0.75	0.26	0.2	0.55	0.56
Net Invested Capital	-0.42	-0.1	0.9	-0.46	0.49	-0.35	0.37	0.46	0.59	0.29	0.59	0.59	0.83	-0.48	0.57	0.61	-0.14	-0.49	-0.23		0.52	0.8	-0.07	0.23	0.62	0.43
Short Long Term Debt	0.36	0.71	0.73	-0.93	0.65	-0.61	0.94	0.89	0.93	0.12	0.93	0.81	0.07	-0.59	0.23	0.96	-0.01	-0.35	0.54	0.52		-0.02	0.21	-0.01	0.87	0.89
Net Working Capital	-0.86	-0.67	0.58	0.15	0.09	0.2	-0.11	-0.17	0.01	0.05	0.06	0.06	0.99	0.09	0.33	0.07	-0.31	-0.54	-0.75	0.8	-0.02		-0.1	0.11	0.12	-0.05
Long Term Debt	0.19	0.19	0.02	-0.11	0.34	0.09	0.14	0.01	0.16	0.04	0.24	0.26	-0.09	0.19	0.02	0.22	-0.19	0.12	0.26	-0.07	0.21	-0.1		0.09	0.31	0.3
Capital Stock	0.13	0.14	0.33	-0.14	0.7	-0.33	-0.32	0.14	0.29	0.98	0.33	0.43	0.14	-0.37	0.39	0.19	0.79	0.55	0.2	0.23	-0.01	0.11	0.09		0.3	-0.14
Property Plant And Equipment Net	0.36	0.62	0.75	-0.85	0.81	-0.64	0.68	0.82	0.94	0.41	0.95	0.98	0.2	-0.67	0.55	0.95	0.12	-0.26	0.55	0.62	0.87	0.12	0.31	0.3		0.85
Short Long Term Debt Total	0.39	0.63	0.6	-0.85	0.57	-0.54	0.88	0.8	0.8	-0.02	0.78	0.8	0.02	-0.52	0.16	0.83	-0.11	-0.36	0.56	0.43	0.89	-0.05	0.3	-0.14	0.85

Click cells to compare fundamentals

Skye Bioscience, Account Relationship Matchups

Skye Bioscience, fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	410.6K	341.8K	954.9K	7.6M	8.3M	4.7M
Total Current Liabilities	970.8K	787.2K	3.9M	12.1M	13.9M	14.6M
Net Tangible Assets	(15.6M)	548.1K	450.8K	5.9M	6.7M	7.1M
Retained Earnings	(32.2M)	(38.7M)	(47.3M)	(66.7M)	(104.4M)	(99.2M)
Accounts Payable	129.8K	381.4K	900.0K	1.8M	1.2M	653.5K
Other Current Assets	12.1K	195.0K	629.1K	412.0K	11.0M	11.5M
Total Current Assets	2.0M	2.7M	9.6M	8.9M	11.7M	12.2M
Common Stock	182.9K	288.1K	476.1K	913.5K	12.3K	11.7K
Property Plant Equipment	3.4K	2.0K	7.3K	234.7K	269.9K	283.4K
Total Assets	2.0M	2.7M	9.9M	9.1M	11.9M	6.0M
Total Stockholder Equity	548.1K	450.8K	5.9M	(3.0M)	(2.1M)	(2.2M)
Cash	1.8M	2.5M	9.0M	1.2M	1.3M	1.2M
Non Current Assets Total	2.0K	7.3K	243.0K	167.4K	289.6K	304.0K
Common Stock Shares Outstanding	182.9M	1.0M	1.7M	493.7M	7.0M	6.7M
Non Current Liabilities Total	477.9K	1.4M	78.7K	1.7M	171.2K	162.7K
Total Liab	1.4M	2.2M	4.0M	12.1M	14.1M	8.3M
Net Invested Capital	935.1K	1.9M	7.8M	(1.2M)	2.2M	2.4M
Net Working Capital	1.0M	1.9M	5.7M	(3.2M)	(2.3M)	(2.4M)
Capital Stock	182.9K	288.1K	476.1K	913.5K	12.3K	11.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:

How To Invest In Skye

Details

Is Skye Stock a good investment?

Details

What is Skye Bioscience,'s Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.60)

Return On Assets

(0.30)

Return On Equity

(0.55)

The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Skye Other Current Assets vs Other Current Liab Analysis

Other Current Assets vs Other Current Liab

Other Current Assets vs Other Current Liab Correlation Analysis

Correlation Coefficient

Other Current Assets

Other Current Liab

Skye Bioscience, fundamental ratios Correlations

Skye Bioscience, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Skye Bioscience, fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Property Plant Equipment
Net Working Capital	+ 0.99	Total Stockholder Equity
Property Plant Equipment	+ 0.98	Total Current Assets
Non Current Assets Total	+ 0.98	Total Current Assets
Capital Stock	+ 0.98	Common Stock
Property Plant And Equipment Net	+ 0.98	Total Assets

Other Stockholder Equity	- 0.99	Retained Earnings
Total Current Assets	- 0.95	Retained Earnings
Short Long Term Debt	- 0.93	Retained Earnings
Non Current Assets Total	- 0.91	Retained Earnings
Property Plant Equipment	- 0.9	Retained Earnings
Other Liab	- 0.88	Other Stockholder Equity